View in EDS

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
Authors: Jackovich A; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Gitlitz BJ; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Tiu-Lim JWW; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Duddalwar V; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., King KG; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., El-Khoueiry AB; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Thomas JS; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Tsao-Wei D; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Quinn DI; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Gill PS; Rutgers New Jersey Medical School, Newark, NJ 07103, USA., Nieva JJ; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.
Source: Oncotarget [Oncotarget] 2024 Jul 10; Vol. 15, pp. 444-458. Date of Electronic Publication: 2024 Jul 10.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38985143
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jackovich+A%22">Jackovich A</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Gitlitz+BJ%22">Gitlitz BJ</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Tiu-Lim+JWW%22">Tiu-Lim JWW</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Duddalwar+V%22">Duddalwar V</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22King+KG%22">King KG</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22El-Khoueiry+AB%22">El-Khoueiry AB</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Thomas+JS%22">Thomas JS</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Tsao-Wei+D%22">Tsao-Wei D</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Quinn+DI%22">Quinn DI</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.<br /><searchLink fieldCode="AU" term="%22Gill+PS%22">Gill PS</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.<br /><searchLink fieldCode="AU" term="%22Nieva+JJ%22">Nieva JJ</searchLink>; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101532965%22">Oncotarget</searchLink> [Oncotarget] 2024 Jul 10; Vol. 15, pp. 444-458. <i>Date of Electronic Publication: </i>2024 Jul 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Impact+Journals%22">Impact Journals </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101532965 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1949-2553 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219492553%22">19492553 </searchLink><i>NLM ISO Abbreviation: </i>Oncotarget <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38985143
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.18632/oncotarget.28605
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 444
    Titles:
      – TitleFull: Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jackovich A
      – PersonEntity:
          Name:
            NameFull: Gitlitz BJ
      – PersonEntity:
          Name:
            NameFull: Tiu-Lim JWW
      – PersonEntity:
          Name:
            NameFull: Duddalwar V
      – PersonEntity:
          Name:
            NameFull: King KG
      – PersonEntity:
          Name:
            NameFull: El-Khoueiry AB
      – PersonEntity:
          Name:
            NameFull: Thomas JS
      – PersonEntity:
          Name:
            NameFull: Tsao-Wei D
      – PersonEntity:
          Name:
            NameFull: Quinn DI
      – PersonEntity:
          Name:
            NameFull: Gill PS
      – PersonEntity:
          Name:
            NameFull: Nieva JJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 07
              Text: 2024 Jul 10
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1949-2553
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Oncotarget
              Type: main
ResultId 1